CEDAR KNOLLS, NJ--(Marketwired - Feb 23, 2015) - MYOS Corporation ("MYOS" or the "Company") (MYOS), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, announced today that the Company's abstract, "The Effects of Fertilized Egg Yolk Isolates on Anabolic and Catabolic Signaling in Skeletal Muscle," was accepted for poster presentation at the Experimental Biology Conference focused on cross-disciplined research, being held March 28-April 1, 2015 in Boston, MA.
The presentation will highlight three key molecular signaling pathways in which Fortetropin™ is active. In addition to reducing serum myostatin levels, Fortetropin™ affects the mTOR and Ubiquitin signaling pathways to assist in the growth and maintenance of healthy muscle. These pathways regulate both protein synthesis and muscle growth, in addition to preventing muscle degradation. The study was conducted at the Department of Health Sciences and Human Performance at The University of Tampa by Jacob Wilson, Ph.D., CSCS*D, Assistant Professor and Director of the Skeletal Muscle and Sports Nutrition Laboratory.
Commenting on these research activities, Robert Ashton, M.D., Chief Medical Officer of MYOS, said, "We are excited that our abstract has been selected for presentation at the Experimental Biology Conference as we expect the increasing visibility will foster new research collaborations at MYOS aimed at uncovering the broad clinical potential of Fortetropin™. This data highlights the importance of Fortetropin's ability to act in more than one pathway, and enables us to broaden our research and indications for clinical use. Myostatin and Ubiquitin are key pathways for loss of muscle and aging population and targeting these pathways may allow one to combat the normal aging process."
Maghsoud Dariani, MS, head of science and technology at MYOS, added, "MYOS is committed to continuing its research to further elucidate the mechanism of action of Fortetropin™. We believe that a thorough understanding of Fortetropin's mechanism of action will allow MYOS to evaluate its potential clinical efficacy for diseases characterized by loss of lean muscle and cachexia."
About MYOS Corporation
MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin™, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com.
The Company's first commercial product containing Fortetropin™ (MYO-T12), is distributed by Maximum Human Performance (MHP) under the brand name MYO-X® and is currently available on popular retailer websites including http://mhpstrong.com, www.bodybuilding.com, www.amazon.com and in specialty retailers including GNC and Vitamin Shoppe and others. MYOS believes that Fortetropin, as well as future products it envisions, will redefine existing standards for muscle health.
Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin™ and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, customer demand for our products, market acceptance of our existing and future products, the ability to create new products through research and development including the research described herein, growth in our revenue, the successful entry into new markets including the age management market, the ability to successfully develop and launch our own core branded products, the ability to collect our accounts receivable from our distributors, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin™ and MYO-X®, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to enter into strategic relationships with new distributors, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug Administration. Our products are not intended to diagnose, treat, cure or prevent any disease.